Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Schwaz – page 3

373 clinical trials in Schwaz, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Schwaz at a glance
373
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

373 trials in Schwaz

Open in trial search

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Intellia Therapeutics Inc.

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Astrazeneca AB

Efficacy and Safety of Intravitreal MK-8748 Compared with Aflibercept in Adults with Diabetic Macular Edema

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Merck Sharp & Dohme LLC

A Phase II Randomized, Double‑Blind Study of RO7568282 for Safety and Efficacy in Early‑Stage Parkinson’s Disease Patients

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Study on Protamine Sulfate for Reducing Bleeding and Ischemic Events in Adults with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Protamine Sulfate
  • Sponsor:Klinikum Der Universitat Munchen AöR

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Safety of Two Doses of Siplizumab Compared with Rabbit Anti‑Human Thymocyte Immunoglobulin in Kidney Transplant Recipients Receiving Standard Immunosuppression

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Siplizumab
  • Sponsor:Itb-Med LLC

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sapablursen
  • Sponsor:Deciphera Pharmaceuticals Inc.

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Schwaz

What the registry says about research in the country

01 Advanced Breast Cancer Research

Clinical trials focusing on HER2-positive breast cancer treatment, evaluating novel combination therapies with tucatinib, pertuzumab, and trastuzumab for patients with advanced or metastatic disease.

  • Treatment Evaluation
  • Disease Progression Assessment
  • Combination Therapy

Research aims to measure progression-free survival using established evaluation criteria.

02 Targeted Therapy Studies

Investigation of elacestrant plus everolimus in treating patients with specific breast cancer subtypes, particularly focusing on those with estrogen receptor-positive and HER2-negative disease.

  • ESR1-Mutation Research
  • Endocrine Therapy
  • CDK4/6 Inhibitor Studies

Double-blind studies examining effectiveness in patients who have progressed after previous treatments.

03 Precision Medicine Applications

Advanced research incorporating biomarker-driven approaches in breast cancer treatment, with specific focus on hormone receptor status and genetic mutations.

  • Biomarker Analysis
  • Treatment Resistance
  • Personalized Medicine

Studies utilize imaging review committees to ensure accurate assessment of treatment outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.